TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.

Robert I Haddad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.